A weight-based dose regimen of Uptravi for PAH kids achieves similar drug exposure as the standard dose regimen for adults, a ...

In addition to PH, columnist Jolie Lizana faces a possible scleroderma diagnosis, as coexisting conditions continue to ...

Columnist Anna Jeter shares several ways she's managing stage 3 kidney disease, which she developed after her heart-lung ...

Yutrepia, an inhaled dry powder formulation of treprostinil, has been prescribed to more than 2,800 patients since its ...

Women with pulmonary hypertension have a lower risk of death than men, suggesting sex should be considered as a risk factor, ...

People living with CTEPH face significant symptoms that affect daily life, even when receiving treatment, a real-world U.S.

Researchers in China report that a simple heart ultrasound measure of left ventricular underfilling is a valuable prognostic ...

Early diagnosis of pulmonary arterial hypertension improves five-year survival by 42%, compared with delayed diagnosis, a ...

Pulmonary hypertension life expectancy and prognosis can vary broadly, but have improved in the era of modern treatment.

Instead of resolutions, columnist Jen Cueva suggests a strategy that better reflects the reality of living with a rare disease like PH.

Researchers have pinpointed Jagged-2, a signaling protein, as a potential therapeutic target for slowing or halting the progression of pulmonary arterial hypertension (PAH), based on a rat study.